What Advair? GSK Plays Up Budding Oncology Pipeline In Q4 Call
GSK said its oncology pipeline has doubled in size since July to include 16 assets in the clinic and highlighted the newly in-licensed bifunctional immunotherapy M7824.
You may also be interested in...
Daily round-up of news and notes from the 2019 J.P. Morgan Healthcare Conference in San Francisco: Biogen may be looking for gene therapy partner, Lilly CEO says Loxo is just the start, GSK plays up its BCMA, Amgen vows to put money into deals, Biohaven readies oral CGRP inhibitor to compete, and Roche talks value-based payments.
The UK major is marking its return to oncology by spending over $5bn to get hold of Tesaro and its PARP inhibitor Zejula. The question now is whether it will be able to catch AstraZeneca's market-leading Lynparza.
With few near-term catalysts, GSK's R&D strategy may leave some investors underwhelmed, but President-R&D Hal Barron is focused on making deep cultural and scientific changes at the big pharma. He laid out his initial turnaround plan July 25.